Less pessimistic long-term results for patients with cytomegalovirus disease

Clinical Infectious Diseases

Volumn 47, Issue 10, 2008, Pages 1360-1361

  Scemla, Anne ^a   Kreis, Henri ^a   Legendre, Christophe ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; IMMUNOGLOBULIN ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT SURVIVAL; HUMAN; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL RATE; SURVIVAL TIME;

CYTOMEGALOVIRUS INFECTIONS; HUMANS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 54249132504     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592749     Document Type: Letter

References (3)

1. Arthurs S, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46:840-6.
2. Lowance D, Neumayer HH, Legendre C, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-70.
3. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.